A Non-interventional Retrospective Study to Describe Early Clinical Experience With Cabozantinib in Patients With Advanced Renal Cell Carcinoma (RCC) in the UK

Ipsen

Status: Completed

Conditions: Advanced Renal Cell Carcinoma

Study type: Observational

Funder types: Industry

Identifiers

NCT03696407

A-GB-60000-017

Details and patient eligibility

About

Clinical experience with cabozantinib is limited in the UK and Ireland and there is anecdotal evidence of there being variability between clinicians in terms of where cabozantinib is used in the treatment pathway. The present study aims to collate and report the experiences of a sample of National Health Service (NHS) Trusts that enrolled patients onto the managed access programme. The study will describe the positioning of cabozantinib in the treatment pathway, associated clinical outcomes and characteristics of patients with advanced RCC receiving cabozantinib in this early clinical experience setting. The results will provide valuable information for collective learning on how to prescribe and manage cabozantinib and its optimal positioning in the patient pathway. Overall, the findings will contribute to a better understanding of how best to manage patients with advanced RCC in routine practice.

Enrollment: 108 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• A diagnosis of advanced RCC
• Prescribed cabozantinib as part of the Managed Access Programme (MAP) (alive or deceased at study data collection)
• Aged ≥18 years at start of cabozantinib treatment.

Exclusion criteria

• Decline or lack the capacity to consent for researcher access to their medical records (if living)
• Hospital medical records are unavailable for review